On Tuesday February 20th, 3pm GMT/ 10am EST Luxcel Biosciences will host a webinar given by Prof. Adrian L Harris, a lead cancer researcher and professor of Medical Oncology at the University of Oxford. Titled “Hypoxia in Cancer Biology, what it does and how to measure it,” the talk will outline the role of hypoxia in therapy resistance radio therapy and many other modalities, as well as the role of HIF and HIF targets in tumour biology. It will also discuss relevant in vitro experimental models, and introduce new approaches being developed by the EC-funded MetaCell-HS consortium, combining advanced plate reader technologies (CLARIOstar® with ACU, BMG Labtech) and intracellular fluorescent probes (MitoXpress® Intra Intracellular Oxygen Assay, Luxcel Biosciences) to enable researchers to monitor and control cellular oxygenation in vitro.
Hypoxia is a key feature of most solid tumours and underlies many of the processes associated with how cancer progresses; including tumour cell survival and proliferation, genetic instability, immune responses, angiogenesis, invasion and metastasis and metabolic adaptive responses. Hypoxia inducible factors (HIFs) are a highly evolutionarily conserved family of dimeric transcription factors that are central to mediating the cellular response to hypoxia by regulating the expression of a diverse array of targets. Hypoxia and HIF activation is associated with treatment failure, resistance and poor clinical outcomes. Thus, its analysis in vitro, and in vivo, is a key part of tumour biology and translational research.
REGISTER NOW for this free webinar with top cancer researcher Prof. Adrian Harris.
About the Speaker
Prof. Adrian L Harris is the Cancer Research UK Professor of Medical Oncology at the University of Oxford and directs the Cancer Research UK Molecular Oncology Laboratories at the Weatherall Institute of Molecular Medicine (WIMM). His major laboratory interests involve the role of hypoxia in breast tumour biology, and tumour angiogenesis, the metabolic response to hypoxia, microRNAs induced by hypoxia and hypoxia-induced cell death. He has conducted many predictive and prognostic studies and early exploratory phase trials in new drug development and molecular pathology to translate laboratory findings to clinical relevance and development of new agents